Christopher Kirkham: Could Platelet Activation Become a Liability for Your Antibody Programme?
Christopher Kirkham, Group Leader in Ex Vivo Biology at IQVIA Laboratories, shared a post on LinkedIn:
“Could platelet activation become a liability for your antibody programme?
Platelet safety is often overlooked until a signal emerges during development. However, unintended interactions with platelets can have significant consequences, including platelet depletion, activation and thrombotic complications.
Early assessment of platelet binding, activation and function can help identify potential liabilities before they become costly development challenges.
At IQVIA Laboratories, we combine flow cytometry and aggregometry to provide a comprehensive ex vivo assessment of antibody-mediated platelet responses, supporting more informed candidate selection and risk assessment earlier in development.”

Stay updated with Hemostasis Today.
-
Nov 17, 2026, 01:27X. Long Zheng: Optimizing Treatment in Immune TTP
-
Nov 16, 2026, 15:35Jim Hoffman: Could Blood Purification Change the Fight Against Cancer?
-
Nov 16, 2026, 15:16How Do Artificial Hearts Affect Platelet Function? – Platelets Journal
-
Nov 16, 2026, 15:10Assessing Coagulation Activation in DOAC – Treated Patients – JTH
-
Nov 16, 2026, 15:00Davide Antonio Mei: Should Anticoagulation Continue After AF Ablation?
-
Nov 16, 2026, 14:55Danielle Boyle: Beyond Platelet Counts – Why Patient Stories Matter
-
Nov 16, 2026, 14:28Jan Sloves: The Future of Vascular Ultrasound
-
Nov 16, 2026, 13:49Bahman Rasouli: A Rare Vascular Manifestation of Recurrent Papillary Thyroid Carcinoma
-
Nov 16, 2026, 13:28Muhammad Danyal: Platelet Patterns in Hepatitis B and C